Dyne Therapeutics recently reported encouraging Phase 1/2 clinical data in myotonic dystrophy type 1 and Duchenne muscular dystrophy. At the J.P. Morgan Healthcare Conference, CEO Joshua Brumm said Dyne’s existing cash combined with the new capital is expected to last through 2025—well beyond the next key milestones for both therapeutic candidates.
Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Though GSK divested much of its oncology assets to Novartis in 2015, the company has built back through a internal R&D and business development deals. GSK Senior Vice President, Global Head of Oncology, R&D Hesham Abdullah explained the company’s evolving cancer strategy in an interview during the J.P. Morgan Healthcare Conference in San Francisco.
Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference. In a report, the bank said big pharmas are looking for deals involving de-risked assets.
Blue Cross Blue Shield of Massachusetts is leveraging data and value-based contracts to reduce disparities it has observed and publicly revealed within its own patient population, while also providing financial support to groups that help physicians address health equity.
Providers, payers, and life sciences companies have a lot of room for growth using AI, and investors participating in JPM will continue to focus on companies that recognize this and act on it.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
As the annual J.P. Morgan HealthCare Conference kicked off Monday, two pharma giants unveiled deals that give them access to in-vivo gene editing technologies. Pfizer is teaming up with Beam Therapeutics to develop new base-editing therapies while Bayer hopes to develop new medicines with the in-vivo CRISPR editing tools of Mammoth Biosciences.
Medtronic suffered a shocking setback back in 2014 when its Symplicity 3 pivotal trial failed to meet its primary endpoint of reducing blood pressure meaningfully. Now it is gearing up to present new data to the FDA.
Efficacy, safety and reimbursement are all important things for CAR-T makers to figure out, but manufacturing is no less important.
Performance- and time-based payment models - like the one bluebird bio has proposed for LentiGlobin - are especially harder to put into practice in the US than in Europe, some executives said at this week's JPM conference.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
After a bruising second half of the year, more biotech companies could be targeted for buys, along with the possibility of additional large deals.
Fully incorporating value into pricing will require significant effort and investment, the Novartis CEO said. Meanwhile, CVS/Caremark's Larry Merlo said the company's acquisition of Aetna opened opportunities for innovative pricing models.
CEO David Ricks advocates careful approach focused on differentiation of assets in breakout session, while CFO says company has capacity for one transaction per quarter.
With the approval of Loxo's Vitrakvi, pan-cancer drugs and an emphasis on real-world data are likely to become important trends trends this year.
CVS Health Larry Merlo announced the first retail health "concept store" focused on chronic disease opening up in the Houston, Texas market next month at the J.P. Morgan Healthcare Conference in San Francisco.